Luminex (LMNX) 10-Q 29 Apr 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 25, 2014
Entity [Abstract]	'	'
Entity Registrant Name	'Luminex Corp	'
Entity Central Index Key	'0001033905	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	42,523,756
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$77,386	$67,924
Short-term investments	4,516	4,517
Accounts receivable, net	26,994	30,948
Inventories, net	30,850	30,487
Deferred income taxes	6,561	7,265
Prepaids and other	4,014	5,229
Total current assets	150,321	146,370
Property and equipment, net	33,148	32,793
Intangible assets, net	59,275	60,295
Deferred income taxes	11,913	11,913
Goodwill	50,836	50,738
Other	4,463	3,937
Total assets	309,956	306,046
Current liabilities:	'	'
Accounts payable	8,401	10,698
Accrued liabilities	10,783	11,624
Deferred revenue	5,307	4,980
Current portion of long-term debt	1,548	1,194
Total current liabilities	26,039	28,496
Long-term debt	62	463
Deferred revenue	2,374	2,482
Other	5,339	4,985
Total liabilities	33,814	36,426
Stockholders' equity:	'	'
Common stock, $.001 par value, 200,000,000 shares authorized; issued and outstanding: 41,405,235 shares at March 31, 2014; 41,133,653 shares at December 31, 2013	41	41
Preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Additional paid-in capital	297,720	296,931
Accumulated other comprehensive income	186	419
Accumulated deficit	-21,805	-27,771
Total stockholders' equity	276,142	269,620
Total liabilities and stockholders' equity	$309,956	$306,046

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS Parenthetical (USD $)	Mar. 31, 2014	Dec. 31, 2013
Stockholders' equity:	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	41,405,235	41,133,653
Common stock, outstanding (in shares)	41,405,235	41,133,653
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Revenue	$56,561	$53,200
Cost of revenue	16,607	15,243
Gross profit	39,954	37,957
Operating expenses:	'	'
Research and development	11,084	12,714
Selling, general and administrative	19,445	25,766
Amortization of acquired intangible assets	1,020	1,029
Restructuring costs	220	0
Total operating expenses	31,769	39,509
Income (loss) from operations	8,185	-1,552
Interest expense from long-term debt	-6	-28
Other income, net	-19	-7
Income (loss) before income taxes	8,160	-1,587
Income taxes	-2,194	-924
Net income (loss)	5,966	-2,511
Other comprehensive loss:	'	'
Foreign currency translation adjustments	-234	-112
Unrealized gain on available-for-sale securities, net of tax	1	1
Other comprehensive loss	-233	-111
Comprehensive income (loss)	$5,733	($2,622)
Net income (loss) per share, basic	$0.14	($0.06)
Shares used in computing net income (loss) per share, basic	41,209	40,887
Net income (loss) per share, diluted	$0.14	($0.06)
Shares used in computing net income (loss) per share, diluted	41,825	40,887

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net income (loss)	$5,966	($2,511)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	3,928	3,804
Stock-based compensation	1,629	2,432
Deferred income tax expense	678	700
Excess income tax expense from employee stock-based awards	0	274
Loss on sale of assets	5	18
Non-cash restructuring charges	772	0
Other	-192	198
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	4,017	8,095
Inventories, net	-899	-2,404
Other assets	332	-896
Accounts payable	-2,581	-1,731
Accrued liabilities	-2,434	1,777
Deferred revenue	216	263
Net cash provided by operating activities	11,437	10,019
Cash flows from investing activities:	'	'
Purchases of available-for-sale securities	-2,996	-2,995
Sales and maturities of available-for-sale securities	2,997	13,033
Purchase of property and equipment	-3,105	-2,791
Proceeds from sale of assets	0	31
Acquired technology rights	0	-930
Net cash (used in) provided by investing activities	-3,104	6,348
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock	1,102	1,401
Payments for stock repurchases	0	-5,775
Excess income tax expense from employee stock-based awards	0	-274
Net cash provided by (used in) financing activities	1,102	-4,648
Effect of foreign currency exchange rate on cash	27	-219
Change in cash and cash equivalents	9,462	11,500
Cash and cash equivalents, beginning of period	67,924	42,789
Cash and cash equivalents, end of period	$77,386	$54,289

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2014
BASIS OF PRESENTATION [Abstract]	'
BASIS OF PRESENTATION	'
	NOTE 1 — BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the “Company” or “Luminex”) in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the "2013 10-K").
	The Company has two segments for financial reporting purposes: the technology and strategic partnerships (“TSP”) segment and the assays and related products (“ARP”) segment.  See Note 10 — Segment Information.

RESTRUCTURING_RESTRUCTURING

RESTRUCTURING RESTRUCTURING	3 Months Ended
	Mar. 31, 2014
RESTRUCTURING [Abstract]	'
Restructuring and Related Activities Disclosure [Text Block]	'
	NOTE 2 — RESTRUCTURING
	In August 2013, the Company announced a restructuring plan focused on its ARP segment's Newborn Screening Group and its Brisbane, Australia office where automated punching systems are designed and manufactured. The Company has halted development of the newborn screening assay and is exploring strategic alternatives for the intellectual property related to the automated punching systems. In the first quarter of 2014, management determined that it will close the manufacturing facilities in Brisbane, Australia in the current year. The Company reviewed the requirements for held-for-sale and discontinued operations presentation and determined (1) the newborn screening assay development project was not a business and therefore did not qualify for discontinued operations presentation and (2) the automated punching group has not met the requirements for held-for-sale and discontinued operations presentation as of March 31, 2014.
	The Company has recorded pre-tax restructuring charges primarily consisting of non-cash impairment of inventory, intangible assets and property and equipment, together with employee separation costs. The Company measured and accrued the liabilities associated with employee separation costs at fair value as of the date the plan was announced and terminations were communicated to employees, which primarily included severance pay and other separation costs such as outplacement services and benefits. As a result of the organizational change, the Company eliminated approximately 5% of its workforce. In conjunction with the restructuring plan, the Company evaluated its tangible and intangible assets for estimated impairment and recorded non-cash impairment charges of $4.1 million in 2013 and a further impairment of $0.8 million in the first quarter of 2014. The Company determined the fair value of the assets based upon prices for similar assets.  See Note 6 — Goodwill and Other Intangible Assets.
	The Company will continue to review the remaining asset balances related to the automated punching group for possible further impairment until sale or abandonment. The Company will measure and accrue the facilities exit costs at fair value upon the Company's exit. Facilities exit costs will primarily consist of cease-use losses to be recorded upon vacating the facilities and fixed asset impairment.
	The following tables display the charges taken related to the restructuring through March 31, 2014 and a rollforward of the charges to the accrued balance as of March 31, 2014 (in thousands):
	Restructuring Charges				2013 Restructuring Plan
	2013
	Non-cash impairment charges:
	Inventory				$	2,326
	Property and equipment				1,110
	Intangible assets				700
	Employee separation costs				783
	Facility exit costs				—
	Other				50
	Total 2013 charges				$	4,969
	Recorded to cost of revenue				2,551
	Recorded to restructuring costs				$	2,418
	2014
	Non-cash impairment charges:
	Inventory				$	585
	Property and equipment				187
	Intangible assets				—
	Employee separation costs				38
	Facility exit costs				—
	Other				—
	Total 2014 charges				$	810
	Recorded to cost of revenue				590
	Recorded to restructuring costs				$	220
	Rollforward of Accrued Restructuring	March 31, 2014			December 31, 2013
	Balance at beginning of year	$	128		$	—
	Total restructuring charges	810			4,969
	Non-cash impairment charges	(772		)	(4,136		)
	Employee separation payments	—			(655		)
	Facility exit costs	—			—
	Foreign exchange and other adjustments	6			(50		)
	Balance at end of period	$	172		$	128
	The remaining restructuring accrual balance is expected to be paid within the next four months. As such, it is recorded as a current liability within accrued liabilities on the consolidated balance sheet as of March 31, 2014.

INVESTMENTS

INVESTMENTS	3 Months Ended
	Mar. 31, 2014
Investments [Abstract]	'
INVESTMENTS	'
	NOTE 3 — INVESTMENTS
	Marketable Securities
	The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.  Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings.  Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, which approximates the fair value of these investments.   Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale, and are carried at fair market value, with the unrealized gains and losses included in the determination of comprehensive income and reported in stockholders’ equity.  As of March 31, 2014 and December 31, 2013, all of the Company’s marketable securities were classified as available for sale.  Marketable securities are recorded as either short-term or long-term on the balance sheet based on the contractual maturity date.  The fair value of all securities is determined by quoted market prices, market interest rates inputs, or other than quoted prices that are observable either directly or indirectly (as of the end of the reporting period).  Declines in fair value below the Company’s carrying value deemed to be other than temporary are charged against net earnings.
	Available-for-sale securities consisted of the following as of March 31, 2014 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income		Estimated Fair Value
	Current:
	Money Market funds	$	45,843	$	—	$	—	$	45,843
	Non-government sponsored debt securities	4,516		—		—		4,516
	Total current securities	50,359		—		—		50,359
	Noncurrent:
	Non-government sponsored debt securities	—		—		—		—
	Total noncurrent securities	—		—		—		—
	Total available-for-sale securities	$	50,359	$	—	$	—	$	50,359
	Available-for-sale securities consisted of the following as of December 31, 2013 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income		Estimated Fair Value
	Current:
	Money Market funds	$	46,422	$	—	$	—	$	46,422
	Non-government sponsored debt securities	4,517		—		—		4,517
	Total current securities	50,939		—		—		50,939
	Noncurrent:
	Non-government sponsored debt securities	—		—		—		—
	Total noncurrent securities	—		—		—		—
	Total available-for-sale securities	$	50,939	$	—	$	—	$	50,939
	There were no proceeds from the sales of available-for-sale securities during the three months ended March 31, 2014 or 2013. Realized gains and losses on sales of investments are determined using the specific identification method.  Realized gains and losses are included in other income (expense) in the Consolidated Statements of Comprehensive Income. There are no net unrealized holding losses on available-for-sale securities as of March 31, 2014.
	The estimated fair value of available-for-sale debt securities at March 31, 2014 and December 31, 2013, by contractual maturity, was as follows (in thousands):
		Estimated Fair Value
		March 31, 2014		December 31, 2013
	Due in one year or less	$	4,516	$	4,517
	Due after one year through two years	—		—
		$	4,516	$	4,517
	Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
	Non-Marketable Securities and Other-Than-Temporary Impairment
	The Company owns a minority interest in a private company based in the U.S. through its investment of $1.0 million in the third quarter of 2012.  This minority interest is included at cost in other long-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee as the Company owns less than 20% of the voting equity in the investee and the investee is not publicly traded.
	The Company's other minority interest in a private company was acquired by a third party in July 2013 and, as a result, the Company's minority interest in that private company was sold. The Company realized a gain of $5.4 million on this minority interest investment in the third quarter of 2013.
	The Company regularly evaluates the carrying value of its cost-method investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee's ability to remain in business, such as the investee's liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is judged to be other-than-temporary, the Company will record an other-than-temporary impairment charge in other income, net in the Consolidated Statements of Comprehensive Income (Loss). As the inputs utilized for the Company's periodic impairment assessment are not based on observable market data, this cost-method investment is classified within Level 3 of the fair value hierarchy. To determine the fair value of this investment, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost-method investment's fair value is not estimated as there are no identified events or changes in the circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical.

INVENTORY_NET

INVENTORY, NET	3 Months Ended
	Mar. 31, 2014
Inventory, Net [Abstract]	'
INVENTORIES, NET	'
	NOTE 4 — INVENTORIES, NET
	Inventories are stated at the lower of cost or market, with cost determined according to the standard cost method, which approximates the first-in, first-out method.  The Company routinely assesses its on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. Inventories consisted of the following (in thousands):
		March 31, 2014		December 31, 2013
	Parts and supplies	$	15,107	$	19,002
	Work-in-progress	8,757		4,747
	Finished goods	6,986		6,738
		$	30,850	$	30,487

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENT	'
	NOTE 5 — FAIR VALUE MEASUREMENT
	The Fair Value Measurements and Disclosures Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The ASC describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable:
	Level 1 –	Quoted prices in active markets for identical assets or liabilities.
	Level 2 –	Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 –	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value.  There were no transfers between Level 1, Level 2, or Level 3 measurements for the three month period ended March 31, 2014.
	We record contingent consideration resulting from a business combination at its fair value on the acquisition date. The Company determines the fair value of the contingent consideration based primarily on the timing and probability of success of clinical events or regulatory approvals, the timing and probability of success of meeting commercial milestones, such as sales levels of a specific product, and discount rates. Our contingent consideration liability arose in connection with the GenturaDx, Inc. ("GenturaDx") acquisition. The Company re-evaluates its assumptions for its contingent consideration fair value determinations each quarter. Changes to the fair value of contingent consideration obligations can result from adjustments to discount rates, accretion of the discount rates due to the passage of time, changes in our estimates of the likelihood of or timing of achieving any development or commercial milestones, changes in the probability of certain clinical events or changes in the assumed probability associated with regulatory approval. As a result of changes in assumptions surrounding the probability of success of meeting the timing of commercial milestones contemplated in the GenturaDx acquisition agreement, the Company adjusted the contingent consideration liability related to the GenturaDx acquisition to $0 in 2013. The assumptions related to determining the value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration expense recorded in any given period.
	As of March 31, 2014 and December 31, 2013 the fair value of the Company's long-term debt was approximately $1.5 million and $1.5 million, respectively. The Company’s long-term debt is classified as a Level 3 instrument and the Company has used a discounted cash flow (“DCF”) model to determine the estimated fair value for disclosure purposes as of March 31, 2014 and December 31, 2013, which does not equal its carrying value on the Condensed Consolidated Balance Sheets.  The assumptions used in preparing the DCF model include estimates for (i) the amount and timing of future interest and principal payments and (ii) the rate of return indicative of the investment risk in the ownership of the Technology Partnerships Canada (TPC) debt.  In making these assumptions, the Company considered relevant factors including the likely timing of principal repayments and the probability of full repayment considering the timing of royalty payments based upon total revenue.
	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 (in thousands):
		Fair Value Measurements at March 31, 2014 Using
		Level 1		Level 2			Level 3		Total
	Assets:
	Money Market funds	$	45,843	$	—		$	—	$	45,843
	Non-government sponsored debt securities	—		4,516			—		4,516
		Fair Value Measurements at December 31, 2013 Using
		Level 1		Level 2			Level 3		Total
	Assets:
	Money Market funds	$	46,422	$	—		$	—	$	46,422
	Non-government sponsored debt securities	—		4,517			—		4,517
	Changes in financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the period were as follows (in thousands):
		March 31, 2014		December 31, 2013
	Balance at beginning of year	$	—	$	1,370
	Contingent consideration recorded at acquisition	—		—
	Fair value adjustments	—		(1,370		)
	Balance at end of period	$	—	$	—

GOODWILL_AND_OTHER_INTANGIBLE_

GOODWILL AND OTHER INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL AND OTHER INTANGIBLE ASSETS	'
	NOTE 6 — GOODWILL AND OTHER INTANGIBLE ASSETS
	All of the Company's goodwill relates to one reporting unit, the ARP segment, for goodwill impairment testing.  Goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise. This goodwill is not expected to be deductible for tax purposes.
	The changes in the carrying amount of the Company’s goodwill during the period are as follows (in thousands):
		March 31, 2014			December 31, 2013
	Balance at beginning of year	$	50,738		$	51,128
	Foreign currency translation adjustments	98			(390		)
	Balance at end of period	$	50,836		$	50,738
	The current in-process research and development project is related to the Company's acquisition of GenturaDx, the foundation of our ARIES platform, in 2012 and are scheduled to be completed in 2014.  The estimated aggregate costs to complete these projects are between $4.0 and $7.0 million. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
		Finite-lived									Indefinite-lived
		Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D			Total
	2013
	Balance at December 31, 2012	$	30,030		$	7,986		$	1,941		$	40,627		$	80,584
	Write-off / Impairment	(214		)	(7		)	(20		)	(454		)	(695		)
	Foreign currency translation adjustments	(140		)	(27		)	(41		)	(73		)	(281		)
	Balance at December 31, 2013	29,676			7,952			1,880			40,100			79,608
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Amortization expense	(3,172		)	(787		)	(140		)	—			(4,099		)
	Foreign currency translation adjustments	93			21			38			—			152
	Accumulated amortization balance at December 31, 2013	(16,272		)	(2,326		)	(715		)	—			(19,313		)
	Net balance at December 31, 2013	$	13,404		$	5,626		$	1,165		$	40,100		$	60,295
	Weighted average life (in years)	10			11			9
	2014
	Balance at December 31, 2013	$	29,676		$	7,952		$	1,880		$	40,100		$	79,608
	Foreign currency translation adjustments	29			7			10			—			46
	Balance at March 31, 2014	29,705			7,959			1,890			40,100			79,654
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2013	(16,272		)	(2,326		)	(715		)	—			(19,313		)
	Amortization expense	(789		)	(196		)	(35		)	—			(1,020		)
	Foreign currency translation adjustments	(29		)	(7		)	(10		)	—			(46		)
	Accumulated amortization balance at March 31, 2014	(17,090		)	(2,529		)	(760		)	—			(20,379		)
	Net balance at March 31, 2014	$	12,615		$	5,430		$	1,130		$	40,100		$	59,275
	Weighted average life (in years)	10			11			11
	The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):
	2014 (nine months)	$	2,893
	2015	3,232
	2016	3,100
	2017	2,144
	2018	1,954
	Thereafter	5,852
		19,175
	IP R&D	40,100
		$	59,275

OTHER_COMPREHENSIVE_LOSS_INCOM

OTHER COMPREHENSIVE (LOSS) INCOME	3 Months Ended
	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]	'
Comprehensive Income (Loss) Note	'
	NOTE 7 — OTHER COMPREHENSIVE INCOME (LOSS)
	Other comprehensive income (loss) represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive loss for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments.
	The following table presents the changes in each component of accumulated other comprehensive income (loss), net of tax (in thousands):
		Foreign Currency Items			Available for Sale Investments			Accumulated Other Comprehensive Income Items
	Beginning balance, December 31, 2013	$	419		$	—		$	419
	Other comprehensive (loss) income before reclassifications	(234		)	4			(230		)
	Amounts reclassified from accumulated other comprehensive income	—			(3		)	(3		)
	Net current-period other comprehensive (loss) income	(234		)	1			(233		)
	Ending balance, March 31, 2014	$	185		$	1		$	186
	The following table presents the tax (expense) benefit allocated to each component of other comprehensive income (loss) (in thousands):
		Three Months Ended March 31, 2014
		Before Tax			Tax Benefit			Net of Tax
	Foreign currency translation adjustments	$	(234	)	$	—		$	(234	)
	Unrealized gains on available-for-sale investments	1			—			1
	Other comprehensive loss	$	(233	)	$	—		$	(233	)

EARNINGS_PER_SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE	'
	NOTE 8 — EARNINGS PER SHARE
	A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts):
		Three Months Ended March 31,
		2014		2013
	Numerator:
	Net income (loss)	$	5,966	$	(2,511	)
	Denominator:
	Denominator for basic net income (loss) per share - weighted average common stock outstanding	41,209		40,887
	Effect of dilutive securities: stock options and awards	616		—
	Denominator for diluted net income (loss) per share - weighted average shares outstanding - diluted	41,825		40,887
	Basic net income (loss) per share	$	0.14	$	(0.06	)
	Diluted net income (loss) per share	$	0.14	$	(0.06	)
	Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period.  Restricted stock (consisting of restricted stock awards, or RSAs, and restricted stock units, or RSUs) and stock options to acquire approximately 0.3 million and 0.9 million shares for the three months ended March 31, 2014 and 2013, respectively, were excluded from the computations of diluted EPS because the effect of including those RSAs, RSUs, and stock options would have been anti-dilutive.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK-BASED COMPENSATION	'
	NOTE 9 — STOCK-BASED COMPENSATION
	The Company’s stock option activity for the three months ended March 31, 2014 was as follows:
	Stock Options (shares in thousands)	Shares		Weighted Average Exercise Price
	Outstanding at December 31, 2013	967		$	15.35
	Granted	—		—
	Exercised	(99	)	8.92
	Cancelled or expired	(11	)	20.5
	Outstanding at March 31, 2014	857		$	16.02
	The Company had $1.5 million of total unrecognized compensation costs related to stock options at March 31, 2014 that are expected to be recognized over a weighted average period of 1.6 years.
	The Company’s restricted share activity for the three months ended March 31, 2014 was as follows:
	Restricted Stock Awards (shares in thousands)	Shares		Weighted Average Grant Price
	Non-vested at December 31, 2013	826		$	18.62
	Granted	516		20.12
	Vested	(214	)	18.33
	Cancelled or expired	(11	)	18.71
	Non-vested at March 31, 2014	1,117		$	19.37
	Restricted Stock Units (in thousands)	Shares
	Non-vested at December 31, 2013	833
	Granted	97
	Vested	(45	)
	Cancelled or expired	(134	)
	Non-vested at March 31, 2014	751
	As of March 31, 2014, there was $22.2 million and $4.8 million of unrecognized compensation cost related to RSAs and RSUs, respectively. That cost is expected to be recognized over a weighted average period of 3.3 years for the RSAs and 2.5 years for the RSUs. The Company issues a small number of cash settled restricted stock units pursuant to the Company's equity incentive plan in certain foreign countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company.
	The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of comprehensive income (in thousands):
		Three Months Ended March 31,
		2014			2013
	Cost of revenue	$	207		$	203
	Research and development	400			647
	Selling, general and administrative	1,022			1,582
	Stock-based compensation costs reflected in net income (loss)	$	1,629		$	2,432

SEGMENT_INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
SEGMENT INFORMATION	'
	NOTE 10 — SEGMENT INFORMATION
	Management has determined that the Company has two segments for financial reporting purposes:  the TSP segment and the ARP segment.  The accounting principles of the segments are the same as those described in the Summary of Significant Accounting Policies in the Company's 2013 Form 10-K.
	Intersegment sales are recorded at fixed prices that approximate the prices charged to third party strategic partners and are not a measure of segment operating earnings. Intersegment sales of approximately $2.0 million and $2.8 million for the quarters ending March 31, 2014 and 2013, respectively, have been eliminated upon consolidation.  The following is selected segment information for the periods indicated (in thousands):
		Three Months Ended March 31, 2014							Three Months Ended March 31, 2013
		TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	32,061	$	24,500		$	56,561	$	31,869	$	21,331		$	53,200
	Depreciation and amortization	1,943		1,985			$	3,928	1,807		1,997			$	3,804
	Operating profit (loss)	9,934		(1,749		)	$	8,185	7,681		(9,233		)	$	(1,552	)

ACCRUED_WARRANTY_COSTS

ACCRUED WARRANTY COSTS	3 Months Ended
	Mar. 31, 2014
Product Warranties Disclosures [Abstract]	'
ACCRUED WARRANTY COSTS	'
	NOTE 11 — ACCRUED WARRANTY COSTS
	Sales of certain of the Company's systems are subject to a warranty.  System warranties typically extend for a period of 12 months from the date of installation not to exceed 24 months from the date of shipment.  The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data.  The actual warranty expense could differ from the estimates made by the Company based on product performance.  Warranty expenses are evaluated and adjusted periodically.
	The following table summarizes the changes in the warranty accrual (in thousands):
	Accrued warranty costs at December 31, 2013	$	721
	Warranty expenses	(184		)
	Accrual for warranty costs	313
	Accrued warranty costs at March 31, 2014	$	850

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 12 — INCOME TAXES
	At the end of each interim reporting period, an estimate is made of the effective tax rate expected to be applicable for the full year.  The estimated full year’s effective tax rate is used to determine the income tax rate for each applicable interim reporting period.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. The effective tax rate for the three months ended March 31, 2014 was 26.88%, including amounts recorded for discrete events. This differs from the statutory rate of 35% primarily because of the worldwide mix of consolidated earnings and losses before taxes and an assessment regarding the realizability of the Company’s deferred tax assets.  The Company’s tax expense reflects the full federal, various state, and foreign blended statutory rates.  The Company is utilizing its net operating losses in the U.S. and Canada; therefore cash taxes to be paid are expected to be in the range of 20%-25% of book tax expense.
	The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, Australia, Canada, China, Hong Kong, Japan, the Netherlands, and various states.  Due to net operating losses, the U.S., Canadian and Australian tax returns dating back to 2009, 2009, and 2010, respectively, can still be reviewed by the taxing authorities.  The Company recorded a reduction in liabilities of $26,000 associated with its uncertain tax positions in the first quarter of 2014.  No other material changes to this liability are expected within the next 12 months.  For the three months ended March 31, 2014, there were no material changes to the total amount of unrecognized tax benefits.  The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 13 - COMMITMENTS AND CONTINGENCIES
	On August 30, 2012 Abbott Laboratories ("Abbott") was named as a defendant in the complaint filed by ENZO Life Sciences, Inc. ("ENZO") in U.S. District Court in Delaware for alleged infringement of its US Patent 7,064,197 as a result of Abbott's distribution of the Company's xTAG Respiratory Viral Panel.  The Company and Abbott have entered into an agreement requiring Luminex to defend and indemnify Abbott for any alleged infringement resulting from its distribution of the Company's xTAG Respiratory Viral Panel. The complaint seeks unspecified monetary damages and injunctive relief.  Abbott filed an answer to the complaint on October 15, 2012.  On November 30, 2012, the Company intervened in the lawsuit. On January 2, 2013 ENZO filed additional claims against the Company, alleging infringement of US Patent 7,064,197 resulting from the Company's sale of its xTAG, FlexScript LDA, SelecTAG, and xMAP Salmonella Serotyping Assay products and alleging infringement of US Patent 8,097,405 resulting from the Company's sale of Multicode products.  The Company filed an answer to ENZO's additional claims on January 28, 2013.  On October 2, 2013 ENZO filed additional claims against the Company, alleging infringement of U.S. Patent 6,992,180 resulting from the Company’s sale of Multicode products.  The Company filed an answer to ENZO’s additional claims on October 21, 2013. A trial date has not been set. The parties to the lawsuit have engaged in the discovery process.
	On November 1, 2013 Irori Technologies, Inc. ("Irori") filed a complaint against the Company in U.S. District Court in the Southern District of California, alleging infringement of its U.S. Patent numbers  6,372,428, 6,416,714, and 6,352,854 resulting from the Company’s sale of its xMAP and xTAG based products. The Company filed a motion to dismiss on January 9, 2014.  Irori filed its response to the Company's motion to dismiss February 7, 2014.  The court granted the motion to dismiss without prejudice on February 25, 2014.  On March 18, 2014, Irori filed an amended complaint, again alleging infringement of its U.S. Patent numbers 6,372,428, 6,416,714, and 6,352,854 resulting from the Company’s sale of its xMAP and xTAG based products.  The complaint seeks unspecified monetary damages and injunctive relief. The Company filed an answer to Irori’s amended complaint on April 2, 2014.  A trial date has not been set.
	When and if it appears probable in management's judgment that the Company will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, liabilities will be recorded in the financial statements and charges will be recorded against earnings.  There can be no assurance that the Company will successfully defend this suit or that a judgment against the Company would not materially adversely affect operating results.
	In January 2013, the Company finalized the termination of its molecular diagnostics distribution agreements and an expense of $7.0 million was recorded in selling, general and administrative expenses in the first quarter of 2013. All payments were made in the second quarter of 2013.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Mar. 31, 2014
Recent Accounting Pronouncements [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	NOTE 14 — RECENT ACCOUNTING PRONOUNCEMENTS
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance requires an entity to present unrecognized tax benefits as a reduction to deferred tax assets when a net operating loss carryforward, similar tax loss or a tax credit carryforward exists, with limited exceptions. For the Company, this Accounting Standards Update is effective for fiscal years beginning on or after December 15, 2013, and for interim periods within those fiscal years. This pronouncement will have no effect on the financial statements as the Company has already been presenting its uncertain tax positions in accordance with this Accounting Standards Update.
	In April 2014, the FASB amended guidance to clarify the accounting for disposals of groups of assets and business units. The amendments alter the definition of a discontinued operation to cover only asset disposals that are a strategic shift with a major effect on an entity's operations and finances. For the Company, the changes should be applied in fiscal years that start on December 15, 2014, or later, but the changes can be applied ahead of the effective date for asset disposals that have not been reported in a set of financial statements. The Company is considering the effect of this amended guidance on the expected disposition of its Brisbane, Australia office where automated punching systems are designed and manufactured.

RESTRUCTURING_RESTRUCTURING_Ta

RESTRUCTURING RESTRUCTURING (Tables)	3 Months Ended
	Mar. 31, 2014
RESTRUCTURING [Abstract]	'
Restructuring and Related Costs [Table Text Block]	'
	Restructuring Charges				2013 Restructuring Plan
	2013
	Non-cash impairment charges:
	Inventory				$	2,326
	Property and equipment				1,110
	Intangible assets				700
	Employee separation costs				783
	Facility exit costs				—
	Other				50
	Total 2013 charges				$	4,969
	Recorded to cost of revenue				2,551
	Recorded to restructuring costs				$	2,418
	2014
	Non-cash impairment charges:
	Inventory				$	585
	Property and equipment				187
	Intangible assets				—
	Employee separation costs				38
	Facility exit costs				—
	Other				—
	Total 2014 charges				$	810
	Recorded to cost of revenue				590
	Recorded to restructuring costs				$	220
	Rollforward of Accrued Restructuring	March 31, 2014			December 31, 2013
	Balance at beginning of year	$	128		$	—
	Total restructuring charges	810			4,969
	Non-cash impairment charges	(772		)	(4,136		)
	Employee separation payments	—			(655		)
	Facility exit costs	—			—
	Foreign exchange and other adjustments	6			(50		)
	Balance at end of period	$	172		$	128
	The remaining restructuring accrual balance is expected to be paid within the next four months. As such, it is recorded as a current liability within accrued liabilities on the consolidated balance sheet as of March 31, 2014.

INVESTMENTS_Tables

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Investments [Abstract]	'
Components of available-for-sale securities	'
	Available-for-sale securities consisted of the following as of March 31, 2014 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income		Estimated Fair Value
	Current:
	Money Market funds	$	45,843	$	—	$	—	$	45,843
	Non-government sponsored debt securities	4,516		—		—		4,516
	Total current securities	50,359		—		—		50,359
	Noncurrent:
	Non-government sponsored debt securities	—		—		—		—
	Total noncurrent securities	—		—		—		—
	Total available-for-sale securities	$	50,359	$	—	$	—	$	50,359
	Available-for-sale securities consisted of the following as of December 31, 2013 (in thousands):
		Amortized Cost		Gains in Accumulated Other Comprehensive Income		Losses in Accumulated Other Comprehensive Income		Estimated Fair Value
	Current:
	Money Market funds	$	46,422	$	—	$	—	$	46,422
	Non-government sponsored debt securities	4,517		—		—		4,517
	Total current securities	50,939		—		—		50,939
	Noncurrent:
	Non-government sponsored debt securities	—		—		—		—
	Total noncurrent securities	—		—		—		—
	Total available-for-sale securities	$	50,939	$	—	$	—	$	50,939
Estimated fair value of available-for-sale debt securities, by contractual maturity	'
	The estimated fair value of available-for-sale debt securities at March 31, 2014 and December 31, 2013, by contractual maturity, was as follows (in thousands):
		Estimated Fair Value
		March 31, 2014		December 31, 2013
	Due in one year or less	$	4,516	$	4,517
	Due after one year through two years	—		—
		$	4,516	$	4,517

INVENTORY_NET_Tables

INVENTORY, NET (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory, Net [Abstract]	'
Schedule of Inventory, Current	'
	Inventories consisted of the following (in thousands):
		March 31, 2014		December 31, 2013
	Parts and supplies	$	15,107	$	19,002
	Work-in-progress	8,757		4,747
	Finished goods	6,986		6,738
		$	30,850	$	30,487

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair value, financial assets (cash equivalents and investments) measured on a recurring basis	'
	The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 (in thousands):
		Fair Value Measurements at March 31, 2014 Using
		Level 1		Level 2			Level 3		Total
	Assets:
	Money Market funds	$	45,843	$	—		$	—	$	45,843
	Non-government sponsored debt securities	—		4,516			—		4,516
		Fair Value Measurements at December 31, 2013 Using
		Level 1		Level 2			Level 3		Total
	Assets:
	Money Market funds	$	46,422	$	—		$	—	$	46,422
	Non-government sponsored debt securities	—		4,517			—		4,517
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	'
	Changes in financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the period were as follows (in thousands):
		March 31, 2014		December 31, 2013
	Balance at beginning of year	$	—	$	1,370
	Contingent consideration recorded at acquisition	—		—
	Fair value adjustments	—		(1,370		)
	Balance at end of period	$	—	$	—

GOODWILL_AND_OTHER_INTANGIBLE_1

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the carrying amount of goodwill	'
	The changes in the carrying amount of the Company’s goodwill during the period are as follows (in thousands):
		March 31, 2014			December 31, 2013
	Balance at beginning of year	$	50,738		$	51,128
	Foreign currency translation adjustments	98			(390		)
	Balance at end of period	$	50,836		$	50,738
Schedule of intangible assets	'
	The current in-process research and development project is related to the Company's acquisition of GenturaDx, the foundation of our ARIES platform, in 2012 and are scheduled to be completed in 2014.  The estimated aggregate costs to complete these projects are between $4.0 and $7.0 million. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives):
		Finite-lived									Indefinite-lived
		Technology, trade secrets and know-how			Customer lists and contracts			Other identifiable intangible assets			IP R&D			Total
	2013
	Balance at December 31, 2012	$	30,030		$	7,986		$	1,941		$	40,627		$	80,584
	Write-off / Impairment	(214		)	(7		)	(20		)	(454		)	(695		)
	Foreign currency translation adjustments	(140		)	(27		)	(41		)	(73		)	(281		)
	Balance at December 31, 2013	29,676			7,952			1,880			40,100			79,608
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2012	(13,193		)	(1,560		)	(613		)	—			(15,366		)
	Amortization expense	(3,172		)	(787		)	(140		)	—			(4,099		)
	Foreign currency translation adjustments	93			21			38			—			152
	Accumulated amortization balance at December 31, 2013	(16,272		)	(2,326		)	(715		)	—			(19,313		)
	Net balance at December 31, 2013	$	13,404		$	5,626		$	1,165		$	40,100		$	60,295
	Weighted average life (in years)	10			11			9
	2014
	Balance at December 31, 2013	$	29,676		$	7,952		$	1,880		$	40,100		$	79,608
	Foreign currency translation adjustments	29			7			10			—			46
	Balance at March 31, 2014	29,705			7,959			1,890			40,100			79,654
	Less: accumulated amortization:
	Accumulated amortization balance at December 31, 2013	(16,272		)	(2,326		)	(715		)	—			(19,313		)
	Amortization expense	(789		)	(196		)	(35		)	—			(1,020		)
	Foreign currency translation adjustments	(29		)	(7		)	(10		)	—			(46		)
	Accumulated amortization balance at March 31, 2014	(17,090		)	(2,529		)	(760		)	—			(20,379		)
	Net balance at March 31, 2014	$	12,615		$	5,430		$	1,130		$	40,100		$	59,275
	Weighted average life (in years)	10			11			11
Estimated aggregate amortization expense for the next five years and thereafter	'
	The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands):
	2014 (nine months)	$	2,893
	2015	3,232
	2016	3,100
	2017	2,144
	2018	1,954
	Thereafter	5,852
		19,175
	IP R&D	40,100
		$	59,275

OTHER_COMPREHENSIVE_LOSS_INCOM1

OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	3 Months Ended
	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	The following table presents the changes in each component of accumulated other comprehensive income (loss), net of tax (in thousands):
		Foreign Currency Items			Available for Sale Investments			Accumulated Other Comprehensive Income Items
	Beginning balance, December 31, 2013	$	419		$	—		$	419
	Other comprehensive (loss) income before reclassifications	(234		)	4			(230		)
	Amounts reclassified from accumulated other comprehensive income	—			(3		)	(3		)
	Net current-period other comprehensive (loss) income	(234		)	1			(233		)
	Ending balance, March 31, 2014	$	185		$	1		$	186
Schedule of Comprehensive Income (Loss)	'
	The following table presents the tax (expense) benefit allocated to each component of other comprehensive income (loss) (in thousands):
		Three Months Ended March 31, 2014
		Before Tax			Tax Benefit			Net of Tax
	Foreign currency translation adjustments	$	(234	)	$	—		$	(234	)
	Unrealized gains on available-for-sale investments	1			—			1
	Other comprehensive loss	$	(233	)	$	—		$	(233	)

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	'
	A reconciliation of the denominators used in computing per share net income, or EPS, is as follows (in thousands, except per share amounts):
		Three Months Ended March 31,
		2014		2013
	Numerator:
	Net income (loss)	$	5,966	$	(2,511	)
	Denominator:
	Denominator for basic net income (loss) per share - weighted average common stock outstanding	41,209		40,887
	Effect of dilutive securities: stock options and awards	616		—
	Denominator for diluted net income (loss) per share - weighted average shares outstanding - diluted	41,825		40,887
	Basic net income (loss) per share	$	0.14	$	(0.06	)
	Diluted net income (loss) per share	$	0.14	$	(0.06	)

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock options activity	'
	The Company’s stock option activity for the three months ended March 31, 2014 was as follows:
	Stock Options (shares in thousands)	Shares		Weighted Average Exercise Price
	Outstanding at December 31, 2013	967		$	15.35
	Granted	—		—
	Exercised	(99	)	8.92
	Cancelled or expired	(11	)	20.5
	Outstanding at March 31, 2014	857		$	16.02
Restricted shares activity	'
	The Company’s restricted share activity for the three months ended March 31, 2014 was as follows:
	Restricted Stock Awards (shares in thousands)	Shares		Weighted Average Grant Price
	Non-vested at December 31, 2013	826		$	18.62
	Granted	516		20.12
	Vested	(214	)	18.33
	Cancelled or expired	(11	)	18.71
	Non-vested at March 31, 2014	1,117		$	19.37
	Restricted Stock Units (in thousands)	Shares
	Non-vested at December 31, 2013	833
	Granted	97
	Vested	(45	)
	Cancelled or expired	(134	)
	Non-vested at March 31, 2014	751
Stock-based compensation costs recognized in consolidated statements of income	'
	The following are the stock-based compensation costs recognized in the Company’s condensed consolidated statements of comprehensive income (in thousands):
		Three Months Ended March 31,
		2014			2013
	Cost of revenue	$	207		$	203
	Research and development	400			647
	Selling, general and administrative	1,022			1,582
	Stock-based compensation costs reflected in net income (loss)	$	1,629		$	2,432

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of segment reporting information by segment	'
	ollowing is selected segment information for the periods indicated (in thousands):
		Three Months Ended March 31, 2014							Three Months Ended March 31, 2013
		TSP Segment		ARP Segment			Consolidated		TSP Segment		ARP Segment			Consolidated
	Revenues from external customers	$	32,061	$	24,500		$	56,561	$	31,869	$	21,331		$	53,200
	Depreciation and amortization	1,943		1,985			$	3,928	1,807		1,997			$	3,804
	Operating profit (loss)	9,934		(1,749		)	$	8,185	7,681		(9,233		)	$	(1,552	)

ACCRUED_WARRANTY_COSTS_Tables

ACCRUED WARRANTY COSTS (Tables)	3 Months Ended
	Mar. 31, 2014
Product Warranties Disclosures [Abstract]	'
Changes in warranty accrual	'
	The following table summarizes the changes in the warranty accrual (in thousands):
	Accrued warranty costs at December 31, 2013	$	721
	Warranty expenses	(184		)
	Accrual for warranty costs	313
	Accrued warranty costs at March 31, 2014	$	850

BASIS_OF_PRESENTATION_Details

BASIS OF PRESENTATION (Details)	Mar. 31, 2014
BASIS OF PRESENTATION [Abstract]	'
Number of segments for financial reporting purposes (in number of segments)	2

RESTRUCTURING_Details

RESTRUCTURING (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'
Asset Impairment Charges	($772)	($4,136)	'
Employee Separation Costs	38	783	'
Facility Exit Costs	0	0	'
Other Restructuring Costs	0	50	'
Total Restructuring Charges	810	4,969	'
Restructuring Charges Included In Cost Of Revenue	590	2,551	'
Restructuring Charges And Associated Cost	220	2,418	'
Employee Separation Payments	0	-655	'
Foreign Exchange and Other Adjustments	6	-50	'
Restructuring Reserve	172	128	0
Restructuring and Related Cost, Number of Positions Eliminated, Percent	5.00%	'	'
Inventories [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Asset Impairment Charges	-585	-2,326	'
Property, Plant and Equipment [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Asset Impairment Charges	-187	-1,110	'
Intangible assets (restructuring) [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Asset Impairment Charges	$0	($700)	'

INVESTMENTS_Details

INVESTMENTS (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Components of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	$50,359,000	'	$50,939,000
Gains in Accumulated Other Comprehensive Gain	0	'	0
Losses in Accumulated Other Comprehensive Gain	0	'	0
Estimated Fair Value	50,359,000	'	50,939,000
Available-for-sale Securities [Abstract]	'	'	'
Proceeds from sales of available-for-sale-securities	0	0	'
Available-for-sale securities, debt maturities [Abstract]	'	'	'
Due in one year or less	4,516,000	'	4,517,000
Due after one year through two years	0	'	0
Total estimated fair value of available-for-sale debt securities	4,516,000	'	4,517,000
Ownership percentage in cost method investment	20.00%	'	'
Money Market Funds [Member]	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	45,843,000	'	46,422,000
Gains in Accumulated Other Comprehensive Gain	0	'	0
Losses in Accumulated Other Comprehensive Gain	0	'	0
Estimated Fair Value	45,843,000	'	46,422,000
Current Non-Government Sponsored Debt Securities [Member]	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	4,516,000	'	4,517,000
Gains in Accumulated Other Comprehensive Gain	0	'	0
Losses in Accumulated Other Comprehensive Gain	0	'	0
Estimated Fair Value	4,516,000	'	4,517,000
Total Current Available-for-sale Securities [Member]	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	50,359,000	'	50,939,000
Gains in Accumulated Other Comprehensive Gain	0	'	0
Losses in Accumulated Other Comprehensive Gain	0	'	0
Estimated Fair Value	50,359,000	'	50,939,000
Non-Current Non-Government Sponsored Debt Securities [Member]	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	0	'	0
Gains in Accumulated Other Comprehensive Gain	0	'	0
Losses in Accumulated Other Comprehensive Gain	0	'	0
Estimated Fair Value	0	'	0
Total Non-Current Available-for-sale Securities [Member]	'	'	'
Components of Available-for-sale Securities [Line Items]	'	'	'
Amortized Cost	0	'	0
Gains in Accumulated Other Comprehensive Gain	0	'	0
Losses in Accumulated Other Comprehensive Gain	0	'	0
Estimated Fair Value	0	'	0
Investment in Private Company 1 [Member]	'	'	'
Available-for-sale securities, debt maturities [Abstract]	'	'	'
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	5,400,000	'	'
Investment in Private Company 2 [Member]	'	'	'
Available-for-sale securities, debt maturities [Abstract]	'	'	'
Amount of investments in a private company	$1,000,000	'	'

INVENTORY_NET_Details

INVENTORY, NET (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory, Net [Abstract]	'	'
Parts and supplies	$15,107	$19,002
Work-in-progress	8,757	4,747
Finished goods	6,986	6,738
Inventory, net	$30,850	$30,487

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Amounts included in asset accounts [Abstract]	'	'
Money Market funds	$45,843,000	$46,422,000
Non-government sponsored debt securities	4,516,000	4,517,000
Amounts included in liability accounts [Abstract]	'	'
Contingent consideration	'	0
Long-term debt	1,500,000	1,500,000
Fair Value, Inputs, Level 1 [Member]	'	'
Amounts included in asset accounts [Abstract]	'	'
Money Market funds	45,843,000	46,422,000
Non-government sponsored debt securities	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Amounts included in asset accounts [Abstract]	'	'
Money Market funds	0	0
Non-government sponsored debt securities	4,516,000	4,517,000
Fair Value, Inputs, Level 3 [Member]	'	'
Amounts included in asset accounts [Abstract]	'	'
Money Market funds	0	0
Non-government sponsored debt securities	$0	$0

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (Fair Value, Inputs, Level 3 [Member], USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Balance at beginning of year	$0	$1,370
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	0	0
Fair value adjustments	0	-1,370
Balance at end of period	$0	$0

GOODWILL_AND_OTHER_INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Goodwill [Roll Forward]	'	'	'
Balance at beginning of year	$50,738,000	$51,128,000	$51,128,000
Foreign currency translation adjustments	98,000	'	-390,000
Balance at end of period	50,836,000	'	50,738,000
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'
Balance, beginning	79,608,000	80,584,000	80,584,000
Write Off Of In Process Research And Development Projects	'	'	-695,000
Foreign currency translation adjustments	46,000	'	-281,000
Balance, ending	79,654,000	'	79,608,000
Less: accumulated amortization [Abstract]	'	'	'
Accumulated amortization, beginning balance	-19,313,000	-15,366,000	-15,366,000
Amortization expense	-1,020,000	-1,029,000	-4,099,000
Foreign currency translation adjustments	-46,000	'	152,000
Accumulated amortization, ending balance	-20,379,000	'	-19,313,000
Net balance	59,275,000	'	60,295,000
Estimated aggregate amortization expense for the next five years and thereafter [Abstract]	'	'	'
2014 (nine months)	2,893,000	'	'
2015	3,232,000	'	'
2016	3,100,000	'	'
2017	2,144,000	'	'
2018	1,954,000	'	'
Thereafter	5,852,000	'	'
Total	19,175,000	'	'
IP R&D	40,100,000	'	'
Total	59,275,000	'	'
In-process Research and Development [Member]	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'
Balance, beginning	40,100,000	40,627,000	40,627,000
Write Off Of In Process Research And Development Projects	'	'	-454,000
Foreign currency translation adjustments	0	'	-73,000
Balance, ending	40,100,000	'	40,100,000
Less: accumulated amortization [Abstract]	'	'	'
Accumulated amortization, beginning balance	0	0	0
Amortization expense	0	'	0
Foreign currency translation adjustments	0	'	0
Accumulated amortization, ending balance	0	'	0
Net balance	40,100,000	'	40,100,000
Technology, Trade Secrets, and Know-how [Member]	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'
Balance, beginning	29,676,000	30,030,000	30,030,000
Write Off Of In Process Research And Development Projects	'	'	-214,000
Foreign currency translation adjustments	29,000	'	-140,000
Balance, ending	29,705,000	'	29,676,000
Less: accumulated amortization [Abstract]	'	'	'
Accumulated amortization, beginning balance	-16,272,000	-13,193,000	-13,193,000
Amortization expense	-789,000	'	-3,172,000
Foreign currency translation adjustments	-29,000	'	93,000
Accumulated amortization, ending balance	-17,090,000	'	-16,272,000
Net balance	12,615,000	'	13,404,000
Weighted average life (in years)	'10 years	'	'10 years
Customer Lists and Contracts [Member]	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'
Balance, beginning	7,952,000	7,986,000	7,986,000
Write Off Of In Process Research And Development Projects	'	'	-7,000
Foreign currency translation adjustments	7,000	'	-27,000
Balance, ending	7,959,000	'	7,952,000
Less: accumulated amortization [Abstract]	'	'	'
Accumulated amortization, beginning balance	-2,326,000	-1,560,000	-1,560,000
Amortization expense	-196,000	'	-787,000
Foreign currency translation adjustments	-7,000	'	21,000
Accumulated amortization, ending balance	-2,529,000	'	-2,326,000
Net balance	5,430,000	'	5,626,000
Weighted average life (in years)	'11 years	'	'11 years
Other Identifiable Intangible Assets [Member]	'	'	'
Finite and Indefinite-lived Intangible Assets [Roll Forward]	'	'	'
Balance, beginning	1,880,000	1,941,000	1,941,000
Write Off Of In Process Research And Development Projects	'	'	-20,000
Foreign currency translation adjustments	10,000	'	-41,000
Balance, ending	1,890,000	'	1,880,000
Less: accumulated amortization [Abstract]	'	'	'
Accumulated amortization, beginning balance	-715,000	-613,000	-613,000
Amortization expense	-35,000	'	-140,000
Foreign currency translation adjustments	-10,000	'	38,000
Accumulated amortization, ending balance	-760,000	'	-715,000
Net balance	1,130,000	'	1,165,000
Weighted average life (in years)	'11 years	'	'9 years
Minimum [Member]	'	'	'
Intangible Assets [Line Items]	'	'	'
Research and Development Expense, Estimated	4,000,000	'	'
Maximum [Member]	'	'	'
Intangible Assets [Line Items]	'	'	'
Research and Development Expense, Estimated	$7,000,000	'	'

OTHER_COMPREHENSIVE_LOSS_INCOM2

OTHER COMPREHENSIVE (LOSS) INCOME (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'
Beginning balance, December 31, 2013	$419	'
Other comprehensive (loss) income before reclassifications	-230	'
Amounts reclassified from accumulated other comprehensive income	-3	'
Net current-period other comprehensive (loss) income	-233	-111
Ending balance, March 31, 2014	186	'
Available-for-sale Securities [Member]	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'
Beginning balance, December 31, 2013	0	'
Other comprehensive (loss) income before reclassifications	4	'
Amounts reclassified from accumulated other comprehensive income	-3	'
Net current-period other comprehensive (loss) income	1	'
Ending balance, March 31, 2014	1	'
Accumulated Translation Adjustment [Member]	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'
Beginning balance, December 31, 2013	419	'
Other comprehensive (loss) income before reclassifications	-234	'
Amounts reclassified from accumulated other comprehensive income	0	'
Net current-period other comprehensive (loss) income	-234	'
Ending balance, March 31, 2014	$185	'

OTHER_COMPREHENSIVE_LOSS_INCOM3

OTHER COMPREHENSIVE (LOSS) INCOME (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'
Foreign currency translation adjustments, before tax	($234)	'
Foreign currency translation adjustments, tax benefit	0	'
Foreign currency translation adjustments, net of tax	-234	'
Unrealized gains on available-for-sale investments, before tax	1	'
Unrealized gains on available-for-sale investments, tax benefit	0	'
Unrealized gains on available-for-sale investments, net of tax	1	'
Other comprehensive (loss) income, before tax	-233	'
Other comprehensive (loss) income, tax benefit	0	'
Other comprehensive (loss) income, net of tax	($233)	($111)

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Numerator:	'	'
Net income (loss)	$5,966	($2,511)
Denominator:	'	'
Denominator for basic net income (loss) per share - weighted average common stock outstanding	41,209,000	40,887,000
Effect of dilutive securities: stock options and awards	616,000	0
Denominator for diluted net income (loss) per share - weighted average shares outstanding - diluted	41,825,000	40,887,000
Basic net income (loss) per share	$0.14	($0.06)
Diluted net income (loss) per share	$0.14	($0.06)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive restricted stock awards, stock options	261,493	886,397

STOCKBASED_COMPENSATION_Detail

STOCK-BASED COMPENSATION (Details) (USD $)	3 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Mar. 31, 2014
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	$1.50
Unrecognized compensation costs, weighted average period of recognition (in years)	'1 year 7 months 2 days
Stock Options [Member]	'
Stock options, outstanding [Roll Forward]	'
Options outstanding, beginning balance (in shares)	967
Granted (in shares)	0
Exercised (in shares)	-99
Cancelled or expired (in shares)	-11
Options outstanding, ending balance (in shares)	857
Stock options, additional Disclosures [Abstract]	'
Weighted-average price, beginning of period (in dollars per share)	$15.35
Weighted-average price, granted (in dollars per share)	$0
Weighted average price, exercised (in dollars per share)	$8.92
Weighted-average price, cancelled or expired (in dollars per share)	$20.50
Weighted-average price, end of period (in dollars per share)	$16.02
Restricted Stock [Member]	'
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	22.2
Unrecognized compensation costs, weighted average period of recognition (in years)	'3 years 3 months 29 days
Equity instruments other than options, nonvested [Roll Forward]	'
Non-vested, beginning balance (in shares)	826
Granted (in shares)	516
Vested (in shares)	-214
Cancelled or expired (in shares)	-11
Non-vested, ending balance (in shares)	1,117
Equity instruments other than options, additional Disclosures [Abstract]	'
Non-vested, beginning balance (in dollars per share)	$18.62
Granted (in dollars per share)	$20.12
Vested (in dollars per share)	$18.33
Cancelled or expired (in dollars per share)	$18.71
Non-vested, ending balance (in dollars per share)	$19.37
Restricted Stock Units (RSUs) [Member]	'
Stock options, additional Disclosures [Abstract]	'
Total unrecognized compensation costs	$4.80
Unrecognized compensation costs, weighted average period of recognition (in years)	'2 years 5 months 19 days
Equity instruments other than options, nonvested [Roll Forward]	'
Non-vested, beginning balance (in shares)	833
Granted (in shares)	97
Vested (in shares)	-45
Cancelled or expired (in shares)	-134
Non-vested, ending balance (in shares)	751

STOCKBASED_COMPENSATION_Detail1

STOCK-BASED COMPENSATION (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cost of revenue	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'
Stock-based compensation costs	$207	$203
Research and development	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'
Stock-based compensation costs	400	647
Selling, general and administrative	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'
Stock-based compensation costs	1,022	1,582
Selling, general and administrative	'	'
Share-based Compensation, allocation and classification in income statements [Abstract]	'	'
Stock-based compensation costs	$1,629	$2,432

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting [Abstract]	'	'	'
Number of segments (in number of segments)	2	'	'
Intersegment sales	$2,000,000	$2,800,000	'
Segment Reporting Information [Line Items]	'	'	'
Revenues from external customers	56,561,000	53,200,000	'
Depreciation and amortization	3,928,000	3,804,000	'
Operating profit (loss)	8,185,000	-1,552,000	'
Assets	309,956,000	'	306,046,000
Technology and Strategic Partnerships [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues from external customers	32,061,000	31,869,000	'
Depreciation and amortization	1,943,000	1,807,000	'
Operating profit (loss)	9,934,000	7,681,000	'
Assays and Related Products [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues from external customers	24,500,000	21,331,000	'
Depreciation and amortization	1,985,000	1,997,000	'
Operating profit (loss)	($1,749,000)	($9,233,000)	'

ACCRUED_WARRANTY_COSTS_Details

ACCRUED WARRANTY COSTS (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Accrued warranty costs [Roll Forward]	'
Accrued warranty costs at December 31, 2013	$721
Warranty expenses	-184
Accrual for warranty costs	313
Accrued warranty costs at March 31, 2014	$850

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Effective tax rate, including amounts recorded for discrete events (in hundredths)	26.88%
Statutory rate (in hundredths)	35.00%
Minimum rate for cash taxes expected to be paid (in hundredths)	20.00%
Maximum rate for cash taxes expected to be paid (in hundredths)	25.00%
Liability associated with its uncertain tax position	$26,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Distribution Agreement Settlement Expense	$7